These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36862438)

  • 1. PI3king apart a rare disease with targeted therapy.
    Newman H; Teachey DT
    Blood; 2023 Mar; 141(9):963-964. PubMed ID: 36862438
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanding rare disease drug trials based on shared molecular etiology.
    Brooks PJ; Tagle DA; Groft S
    Nat Biotechnol; 2014 Jun; 32(6):515-8. PubMed ID: 24911489
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted therapy in rare cancers--adopting the orphans.
    Munoz J; Kurzrock R
    Nat Rev Clin Oncol; 2012 Nov; 9(11):631-42. PubMed ID: 22965154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First CD123-targeted drug approved after wowing in rare cancer.
    Dolgin E
    Nat Biotechnol; 2019 Mar; 37(3):202-203. PubMed ID: 30833771
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel drug targets in 2019.
    Avram S; Halip L; Curpan R; Oprea TI
    Nat Rev Drug Discov; 2020 May; 19(5):300. PubMed ID: 32273590
    [No Abstract]   [Full Text] [Related]  

  • 6. Problems with finding evidence for rare events.
    Kozma CM
    Manag Care Interface; 2004 Nov; 17(11):45-6. PubMed ID: 15573803
    [No Abstract]   [Full Text] [Related]  

  • 7. Care for Rare: Spotlight on Rare Diseases.
    Mukherjee K
    Trends Pharmacol Sci; 2019 Apr; 40(4):227-228. PubMed ID: 30905358
    [No Abstract]   [Full Text] [Related]  

  • 8. Rare disease resources not as rare as one might think.
    Burnworth MT
    Am J Health Syst Pharm; 2013 Jun; 70(12):1013-4. PubMed ID: 23719873
    [No Abstract]   [Full Text] [Related]  

  • 9. The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting.
    Gill J; Sarpatwari A; Prasad V
    Mayo Clin Proc; 2021 Sep; 96(9):2305-2308. PubMed ID: 34481596
    [No Abstract]   [Full Text] [Related]  

  • 10. National specialty pharmacies focus on rare, chronic diseases.
    Thompson CA
    Am J Health Syst Pharm; 2004 Jan; 61(2):133, 138, 140. PubMed ID: 14750398
    [No Abstract]   [Full Text] [Related]  

  • 11. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.
    Hechtelt Jonker A; Hivert V; Gabaldo M; Batista L; O'Connor D; Aartsma-Rus A; Day S; Sakushima K; Ardigo D
    Nat Rev Drug Discov; 2020 Aug; 19(8):495-496. PubMed ID: 32313251
    [No Abstract]   [Full Text] [Related]  

  • 12. Rare pulmonary disease and orphan drugs: a path to the future.
    Harari S; Adir Y; Humbert M
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pfizer explores rare disease path.
    Shaffer C
    Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug target gene-based analyses of drug repositionability in rare and intractable diseases.
    Sakate R; Kimura T
    Sci Rep; 2021 Jun; 11(1):12338. PubMed ID: 34117295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare opportunities appear on the horizon to treat rare diseases.
    Torres C
    Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483
    [No Abstract]   [Full Text] [Related]  

  • 16. Rare-disease drugs to receive consideration on par with serious-disease drugs.
    Thompson CA
    Am J Health Syst Pharm; 2012 Nov; 69(22):1936-7. PubMed ID: 23135552
    [No Abstract]   [Full Text] [Related]  

  • 17. A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.
    Péron J; Marreaud S; Staelens D; Raveloarivahy T; Nzokirantevye A; Flament J; Steuve J; Lia M; Collette L; Schöffski P
    Eur J Cancer; 2019 Mar; 109():192-195. PubMed ID: 30655100
    [No Abstract]   [Full Text] [Related]  

  • 18. SIMD statement on investigational new drugs for rare disease therapies.
    Longo N
    Mol Genet Metab; 2012 Mar; 105(3):367. PubMed ID: 22300846
    [No Abstract]   [Full Text] [Related]  

  • 19. Accessing the accelerated approval pathway for rare disease therapeutics.
    Kakkis ED; Kowalcyk S; Bronstein MG
    Nat Biotechnol; 2016 Apr; 34(4):380-3. PubMed ID: 27054988
    [No Abstract]   [Full Text] [Related]  

  • 20. Importance of transparency in assessing the feasibility of modeling rare disease.
    Johnson SJ; Davis MR; Wang ST
    Med Decis Making; 2015 Feb; 35(2):143-4. PubMed ID: 25505051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.